噻托溴铵联合沙美特罗氟替卡松辅助治疗慢性阻塞性肺疾病的临床效果  

Clinical efficacy of tiotropium bromide combined with fluticasone salmeterol as adjunctive therapy for chronic obstructive pneumonia disease

作　　者：陈书平[1] 冯杰美 陈昌枝[1] 

机构地区：[1]广西贵港市人民医院呼吸内科,贵港市537100

出　　处：《广西医学》2017年第11期1690-1692,共3页Guangxi Medical Journal

摘　　要：目的探讨噻托溴铵联合沙美特罗氟替卡松辅助治疗慢性阻塞性肺疾病(COPD)的临床效果。方法将100例COPD患者随机分为对照组和观察组,每组50例。两组患者均给予常规治疗及沙美特罗氟替卡松吸入剂,观察组在上述治疗的基础上加用噻托溴铵吸入,两组疗程均为3个月。比较两组患者的疗效、治疗前后肺功能指标及外周血Th水平。结果治疗后对照组总有效率为88.0%,观察组总有效率为96.0%,观察组疗效优于对照组(P<0.05)。治疗后两组用力肺活量(FVC)、1 s用力呼气容积(FEV1)、FEV1/FVC值及Th1、Th1/Th2均高于治疗前,并且观察组上述指标均高于对照组(P<0.01)。结论噻托溴铵联合沙美特罗氟替卡松能够提高COPD的治疗效果,有助于改善患者的肺功能及细胞免疫功能。Objective To investigate the clinical efficacy of tiotropium bromide combined with fluticasone salmeterol as adjunctive therapy for chronic obstructive pneumonia disease（ COPD）. Methods A total of 100 patients with COPD were randomly divided into control group and observation group,with 50 cases in each group. The patients in the two groups received routine therapy and fluticasone salmeterol inhalant. The patients in the observation group received inhalation of tiotropium bromide besides that therapy above. The course of treatment was 3 months in both groups. The therapeutic efficacy,lung function index,and Th level of peripheral blood before and after treatment were compared between the two groups. Results After treatment,the total effective rates of the control group and the observation group were 88. 0% and 96. 0% respectively,and the efficacy of the observation group was superior to that of the control group（ P 〈 0. 05）.The forced vital capacity（ FVC）,forced expiratory volume in one second（ FEV1）,FEV1/FVC,Th1 level and Th1/Th2 increased in both groups after treatment compared to the pre-treatment（ P 〈 0. 05）,and the levels of the indices above in the observation group were higher than those in the control group（ P 〈 0. 01）. Conclusion Tiotropium bromide combined with fluticasone salmeterol can improve the therapeutic efficacy on COPD and contribute to improving the lung function and cellular immune function of the patients.

关 键 词：慢性阻塞性肺疾病 噻托溴铵 沙美特罗氟替卡松 

分 类 号：R563[医药卫生—呼吸系统]